PRNewsWire · October 28, 2026

HERVolution Publishes Foundational Data Demonstrating Rationally Engineered HERV-K Antigens Can Break Immune Tolerance and Train Immune Cells to Target Cancer Cells

Get the app for more

Explore stock news, insights and company research.